Position in ANNX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$548,460
New position
Shares Held
99,000
first reported quarter
Ownership
0.050%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SCS Capital Management LLC holds $78,580,010 across 13 Biotechnology names. ANNX ranks #6 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
149,547 | $49,480,615 | |
| 2 | AGIO |
Agios Pharmaceuticals, Inc.
|
612,850 | $20,732,715 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
197,998 | $3,801,561 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
53,430 | $1,062,722 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
9,375 | $786,750 | |
| 6 | ANNX |
Annexon, Inc.
This page
|
99,000 | $548,460 | |
| 7 | FHTX |
Foghorn Therapeutics Inc.
|
106,980 | $511,364 | |
| 8 | ANRO |
Alto Neuroscience, Inc.
|
16,840 | $378,563 |
All Filings in ANNX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $548,460 | 99,000 | Shares | Sole | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||